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Background: The availability of robotic assistance could make laparoscopic pancreaticoduo-
denectomy safely feasible. We herein provide a systematic review on laparoscopic robot-assisted 
pancreaticoduodenectomy (RAPD).
Methods: Literature search was conducted on multiple databases considering articles published 
in English up to October 31, 2014, reporting on ten or more patients.
Results: A total of 262 articles were identified. Excluding duplicates (n=172), studies not 
matching inclusion criteria (n=77), and studies not suitable for other reasons (n=6), a total of 
seven studies reporting on 312 RAPDs were eventually reviewed. These studies were either 
retrospective cohort studies (n=4) or case-matched studies (n=3). No randomized controlled 
trial was identified. Most patients undergoing RAPD were diagnosed with malignant tumors 
(224/312; 71.8%). RAPD was feasible in most patients. Conversion to open surgery was reported 
in 9.2% of the patients. A hybrid RAPD technique, employing standard laparoscopy or open 
surgery through a mini-incision, was adopted in most patients (178/312; 57.0%). Overall, 
there were six postoperative deaths at 30 days (6/312; 1.9%), including one intraoperative 
death caused by portal vein injury, while 137 out of 260 patients with complete information 
developed postoperative complications (52.7%). The mean length of hospital stay ranged from 
10–29 days. Postoperative pancreatic fistula (POPF) occurred in 66 patients (66/312; 21.1%). 
Grade C POPF was reported in eight patients (8/312; 2.5%). The costs of RAPD were assessed 
in two studies, demonstrating additional costs ranging from 4,000–5,000 US dollars to 6,193 
Euro. The mean number of examined lymph nodes and the rate of positive surgical margins 
indicate that RAPD could be an appropriate oncologic operation.
Conclusion: RAPD is safely feasible. These results were obtained in selected patients and in 
specialized centers. RAPD should not be implemented in the occasional patient by surgeons 
without advanced laparoscopic skills and formal training in robotic surgery.
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Introduction
First described in 1994 by Gagner and Pomp,1 laparoscopic pancreaticoduodenectomy 
(PD) is eventually gaining momentum in specialized centers.2 The intrinsic limitations 
of conventional laparoscopy, the lack of standardized training in advanced laparoscopy 
for the earlier generations of pancreatic surgeons, and the technical challenges of PD 
are among the major factors that have limited the acceptance of laparoscopic PD. The 
enhanced dexterity offered by the da Vinci surgical system (dVss) (Intuitive Surgical, 
Sunnyvale, California, USA) offers the unique opportunity to verify if the well-known 
advantages of laparoscopy can be experienced also by patients  undergoing PD.3 
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 Further, the use of the dVss could allow a greater proportion 
of pancreatic surgeons to safely pursue minimally invasive 
PD, since robotic surgery is more intuitive than conventional 
laparoscopy.4
We herein provide a systematic review on robot-assisted 
PD (RAPD).
Methods
Definition of RAPD
For the purpose of this review, all procedures in which the 
dVss was used to perform a PD were defined as RAPD. 
This definition includes patients in whom the operation was 
carried out entirely under robotic assistance and patients in 
whom robotic assistance was limited to specific steps of the 
operation. The latter instance actually represents a hybrid 
procedure in which the use of robotic assistance is mixed 
with traditional laparoscopy and/or with traditional surgery 
carried out through a mini-laparotomy incision. There are 
several prototypes of “hybrid RAPD”:
1. Laparoscopy is used for dissection and robotic assistance 
for digestive reconstruction.5
2. Laparoscopy is used for preliminary dissection and 
robotic assistance for dissection of the posterior margin/
uncinate process and for digestive reconstructions.6
3. Following robotic dissection, digestive reconstruction is 
entirely or partially carried out through a mini-laparotomy 
incision.7
Search methodology
The literature search focused solely on articles published, 
between January 1, 2000 and October 31, 2014, in peer-
reviewed journals and in English. Studies were identified 
by searching multiple literature databases, including Scopus, 
Web of Science, and PubMed using the following keywords: 
“pancreaticoduodenectomy and robot*,” “pancreatoduo-
denectomy and robot*,” and “duodenopancreatectomy and 
robot*.” Queries were limited to clinical studies. Hand 
searches of reference lists of relevant literature reviews were 
also performed.
Selection of studies
Randomized controlled trials, case-matched studies, and 
retrospective cohorts studies were all accepted, if reporting 
on ten or more RAPD.
Data extraction and management
Data were collected on customized tables. Each article was 
read and analyzed by at least two authors. In case of multiple 
Articles identified after database and manual search
n=262
Abstracts assessed for eligibility
n=90
Full-text articles assessed for eligibility
n=13
Studies availabe for review
n=7
Excluded n=6
Excluded n=77
Excluded n=172
Overlapped populations =3
Not relevant =2
(not eligible)
(duplicates)
Few RAPD cases =1
Figure 1 Flowchart of systematic review.
Abbreviation: RAPD, robot-assisted pancreaticoduodenectomy.
Table 1 Reviewed series
Study Year Country Patients Technique
Giulianotti et al8 2010 italy/USA 36 RAPD
Buchs et al10 2011 USA 44 RAPD
Chalikonda et al5 2012 USA 30 Hybrid RAPD
Lai et al11 2012 People’s Republic  
of China
20 RAPD
Zhan et al7 2013 People’s Republic  
of China
16 Hybrid RAPD
Boggi et al9 2013 italy 34 RAPD
Zureikat et al6 2013 USA 132 Hybrid RAPD
Abbreviation: RAPD, robot-assisted pancreaticoduodenectomy.
articles from the same working group, only the most recent 
or the more informative publication was considered in order 
to avoid duplication of the data.
Results
Initial queries identified a total of 262 articles from all 
databases and search methods. Comparison of the retrieved 
titles identified 172 studies that were duplicates, thus leaving 
90 abstracts for further evaluation. Additional 77 studies did 
not meet the inclusion criteria, and six were excluded because 
of various reasons (Figure 1), eventually leaving seven 
studies for the review. These studies were either retrospective 
cohort studies (n=4)6–9 or case-matched studies (n=3),5,10,11 all 
published between 2010 and 2013. No randomized controlled 
trial was identified.
Overall, the seven studies reported data on 312 RAPDs 
(Table 1).
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Table 2 Safety of RAPD
Study Morbidity,  
n (%)
POPF,  
n (%)
Grade C POPF,  
n (%)
30-d mortality,  
n (%)
Mean LOS, 
d (SD)
Giulianotti et al8 NA 13 (36.1) NA 1 (2.7) 28.7 (NA)
Buchs et al10 16 (36.4) 8 (18.1) 1 (2.3) 2 (4.5) 13 (7.5)
Chalikonda et al5 9 (30) 2 (6.6) 1 (3.3) 1 (4) 9.79 (NA)
Lai et al11 10 (50) 7 (35) NA 0 13.7 (6.1)
Zhan et al7 6 (38) 1 (6.3) 0 (0) 0 23 (7)
Boggi et al9 19 (55.8) 13 (38.2) 0 (0) 0 23 (NA)
Zureikat et al6 83 (62.8) 22 (17) 5 (3.7) 2 (1.5) 10 (NA)
Abbreviations: RAPD, robot-assisted pancreaticoduodenectomy; POPF, postoperative pancreatic fistula; LOS, length of hospital stay; d, day; NA, not available.
Table 3 Feasibility of RAPD
Study Conversion Mean operative  
time
Mean blood 
loss
Giulianotti et al8 NA 400.5 minutes 250.0 mL
Buchs et al10 2 (4.5%) 444.0 minutes 387.0 mL
Chalikonda et al5 3 (10%) 476.0 minutes 485.0 mL
Lai et al11 1 (5%) 491.5 minutes 247.0 mL
Zhan et al7 0 479.7 minutes 633.8 mL
Boggi et al9 0 597.0 minutes 220.0 mL
Zureikat et al6 11 (8%) 527.0 minutes NA
Abbreviations: RAPD, robot-assisted pancreaticoduodenectomy; NA, not available.
Current status
Our review shows that just a few hundreds of RAPDs have 
been reported worldwide. The fact that all RAPDs were 
reported in recent years, if on one hand, testifies a growing 
interest around this new technique, on the other, demonstrates 
that this operation is still being performed only by pioneers 
and is yet under development. Perhaps because of this, there 
is no agreement on patient selection criteria. Looking at 
the demographics of the reported series, it seems that older 
patients are avoided (mean patient age ranging from 60.0 to 
66.4 years) and that lean patients are preferred (mean body 
mass index ranging from 24.2 to 27.7 kg/m2). As expected, 
most patients undergoing PD were diagnosed with malignant 
tumors (224/312; 71.8%). Prevalence of malignant tumors 
among reviewed series ranged from 46.0% and 83.3%.
The variability of the techniques used, despite all authors 
employing robotic assistance at least at some stages during 
PD, shows also that most technical details of RAPD have 
to be defined yet. The hybrid approach was used in most 
patients (178/312; 57.0%), but most authors used a fully 
robotic technique (4/7; 57.1%).
Safety
Overall, there were six postoperative deaths at 30 days 
(6/312; 1.9%), while 137 out of 260 patients with com-
plete information developed postoperative complications 
(52.7%). Postoperative pancreatic fistula (POPF) occurred 
in 66 patients (66/312; 21.1%). Grade C POPF was reported 
in eight patients (8/312; 2.5%) (Table 2).
It is worth noting that one intraoperative death occurred 
following injury to the portal vein, despite prompt conver-
sion to open surgery.5
In retrospective cohort studies, postoperative mortality 
(#30 days) ranged from 0% to 2.7% (mean 1.0%), while 
overall morbidity ranged from 38.0% to 62.8% (mean 
52.2%). Incidence of POPF ranged from 6.3% to 38.2% 
(mean 24.4%). Grade C POPF occurred in five out of 
182 patients with complete information (2.7%).
In case-matched studies, postoperative mortality 
(#30 days) ranged from 0% to 4.5% (mean 2.8%), while 
overall morbidity ranged from 30.0% to 50.0% (mean 
38.8%). Incidence of POPF ranged from 6.7% to 35.0% 
(mean 19.9%). Grade C POPF occurred in three out of 
94 patients with complete information (3.1%).
Figures on POPF should be read considering that most 
pancreases (91.2%) were reported as being soft.
The mean length of hospital stay ranged from 10 to 
29 days, possibly reflecting the differences in postoperative 
management and policies on patient discharge from the 
hospitals.
The need for re-operation (#90 postoperative days) 
ranged from 3.0% to 10.0%.
Feasibility
RAPD was feasible in the vast majority of selected patients. 
Conversion to open surgery occurred between 0% and 25.0% 
of the patients.
In retrospective cohort studies, the mean operative time 
ranged from 400.5 to 597.0 minutes with an estimated 
mean intraoperative blood loss ranging from 220.0 mL to 
633.8 mL.
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Table 4 Technical details of RAPD
Study Ports Optic port Fourth  
robotic arm
Energy device Closure  
of GDA
Section of the  
pancreatic neck
Extraction site Drains
Giulianotti et al8 5 Pararectal Right Harmonic scalpel Ligature Harmonic scalpel Pfannenstiel Yes
Buchs et al10 – – – – – – Pfannenstiel Yes
Chalikonda et al5 6 Umbilical No Harmonic scalpel Clips Ultrasonic shear enlarged port site Yes
Lai et al11 5 Sub-umbilical Left Ligasure Clips – Pfannenstiel Yes
Zhan et al7 5 Umbilical Right Harmonic scalpel – – enlarged port site Yes
Boggi et al9 5 Pararectal Left Harmonic scalpel Ligature Scissors Pfannenstiel Yes
Zureikat et al6 8 Para-umbilical Right Ligasure Ligature Cautery hook enlarged port site Yes
Abbreviations: RAPD, robot-assisted pancreaticoduodenectomy; GDA, gastroduodenal artery.
Table 5 Main histopathology parameters
Tumor type Lymph  
nodes,  
n (%)
R0,  
n (%)Malignant,  
n (%)
PDAC Benign, 
n (%)
Giulianotti et al8 24 (67.7%) 13 12 (33.3%) 21 (NA) 24 (100%)
Buchs et al10 33 (75%) 22 11 (25%) 16.8 (10) 30 (90.9%)
Chalikonda et al5 14 (46%) 14 16 (54.5%) 13.2 (NA) 14 (100%)
Lai et al11 15 (75%) 7 5 (25%) 9.87 (6) 11 (73.3%)
Zhan et al7 10 (62.5%) 7 6 (37.5%) NA 10 (100%)
Boggi et al9 22 (64.7%) 5 12 (35.3%) 32 (NA) 22 (100%)
Zureikat et al6 106 (80.3%) 54 26 (19.7%) 19 (NA) 93 (87.7%)
Abbreviations: PDAC, pancreatic ductal adenocarcinoma; NA, not available; R0, margin negative resection.
Mean length of hospital stay
Study name Statistics for each study Difference in means and 95% CI
Difference
in means
Standard
error
Lower
limit
Upper
limit Z-valueVariance
Buchs et al10 1.600
3.470
12.100
4.600
1.891
1.677
3.794
2.291
3.576
2.812
14.398
5.249
−2.106
−20.00 −10.00 0.00 10.00 20.00
0.183
4.663
0.109
5.306
6.757
19.537
9.090
0.846
2.069
3.189
2.008
0.398
0.039
0.001
0.045
Favors
open PD
Favors
RAPD
Lai et al11
Chalikonda et al5
P-value
Figure 2 Meta-analysis of mean length of hospital stay.
Abbreviations: RAPD, robot-assisted pancreaticoduodenectomy; PD, pancreaticoduodenectomy; CI, confidence interval.
Mean number of examined lymph nodes
Study name Statistics for each study Difference in means and 95% CI
Difference
in means
Standard
error
Lower
limit
Upper
limit Z-valueVariance
Buchs et al10 5.80
1.50
0.50
2.30
2.44
1.29
4.05
1.10
5.97
1.67
16.37
1.21
1.01
−15.00 −7.50 0.00 7.50 15.00
−1.03
−7.42
0.14
10.59
4.03
8.44
4.45
2.37
1.16
0.13
2.09
0.02
0.25
0.9
0.04
Favors
open PD
Favors
RAPD
Lai et al11
Chalikonda et al5
P-value
Figure 3 Meta-analysis of mean number of examined lymph nodes.
Abbreviations: RAPD, robot-assisted pancreaticoduodenectomy; PD, pancreaticoduodenectomy; CI, confidence interval.
Table 6 Meta-analysis of RAPD vs open PD (P-values)
Study Operative  
time
LOS R0 Lymph  
nodes
Malignant  
tumors
Morbidity POPF Mortality
Buchs et al10 0.001* 0.398 0.362 0.018* 0.558 0.257 0.788 0.634
Chalikonda et al5 0.000* 0.039* 0.123 0.245 1.000 0.286 0.242 0.494
Lai et al11 0.008* 0.001* 0.738 0.9 0.697 0.293 0.111 0.775
Meta-analysis 0.249 0.045* 0.241 0.033* 0.869 0.210 0.717 0.605
Note: *P,0.005.
Abbreviations: RAPD, robot-assisted pancreaticoduodenectomy; PD, pancreaticoduodenectomy; LOS, length of hospital stay; POPF, postoperative pancreatic fistula; 
R0, margin-negative resection.
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In case-matched studies, the mean operative time ranged 
from 444.0 to 491.5 minutes with an estimated mean intra-
operative blood loss ranging from 247.0 mL to 485.0 mL 
(Table 3).
Table 4 summarizes some of the technical details of 
RAPD.
Pancreatic remnants were managed according to different 
techniques. Most pancreata (113/317; 35.7%) were drained 
either into the jejunum (97/113; 85.8%) or into the stomach 
(16/113; 5.0%). Duct occlusion (48/317; 15.1%) was also 
employed by Giulianotti and Zhan.7,8 Information on the use 
of a duct stent was missing in most series.
effectiveness
Table 5 summarizes pathological parameters. Most patients 
(224/317; 70.6%) were operated on because of malignant 
tumors, though only a minority were diagnosed with ductal 
adenocarcinoma of the pancreas (122/317; 38.5%). The mean 
number of examined lymph nodes and the rate of positive 
surgical margins indicated that RAPD could be an appropriate 
operation for selected patients diagnosed with periampullary 
and pancreatic tumors.
Unfortunately, the issue of costs was addressed only in two 
manuscripts. Both reported additional costs, as compared to 
open surgery. Boggi et al estimated the additional costs to be 
6,193 Euro per patient.9 Similarly, Chalikonda et al estimated 
the additional costs of RAPD at 4,000–5,000 US dollars.5
To further elucidate the effectiveness of RAPD, we con-
ducted a meta-analysis on the three case-matched studies that 
are currently available.5,10,11 Overall, there were 136 open PDs 
and 94 RAPDs. The following parameters were evaluated: 
operative time, length of hospital stay, rate of margin-free 
(R0) resection, number of examined lymph nodes, prevalence 
of malignant tumors, postoperative morbidity, incidence of 
POPF, and postoperative mortality.
RAPD appeared to be associated with a shorter length 
of hospital stay (Figure 2) and a higher lymph node yield 
(Figure 3) (Table 6).
Potential selection biases
None of the studies available was prospective and  randomized. 
Because of the retrospective nature of examined studies, and 
hence the lack of prospective selection criteria, patients were 
operated on because of a variety of pancreatic and periampul-
lary diseases, including both benign and malignant tumors. 
Crucial information, such as tumor stage, is missing. Pancre-
atic and periampullary tumors are indeed staged differently 
based on tumor type.
Case-matched studies also showed differences between 
comparison groups. In the study from Buchs et al,10 the two 
study groups were mismatched for age (P=0.04), body mass 
index (P=0.01), and ASA class (P=0.01). Further, patients 
with different tumor types were treated, and the technique 
used for pancreatic anastomosis was also different between 
study groups (P=0.0001). In the studies by Chalikonda et al5 
and Lai et al,11 different types of tumors were treated in the 
study groups.
incomplete outcome data
Again, because of the retrospective design of available 
 studies, considerable information was missing or  incomplete. 
Cost analysis, for instance, was available in only two 
studies.
Conclusion and future perspectives
The intrinsic technical difficulties of open PD have put gen-
erations of surgeons to the test, and the challenge continues 
nowadays. As a consequence, laparoscopic PD has remained 
one the last fortress of open surgery though a few gifted 
surgeons have safely implemented this operation in a large 
series of patients,12–15 even when dealing with the resection 
and reconstruction of the superior mesenteric/portal vein.16 
The intrinsic limitations of laparoscopy, however, make these 
achievements difficult to duplicate on a large scale.
The dVss is not a robot in the narrower sense of the term, 
since it is not capable of any autonomous or programmed 
action. It is rather a telepresence manipulator able to duplicate 
the movements of surgeon’s hands at the tip of miniaturized 
wristed instruments, having seven degrees of freedom like 
the human wrist. Further, the dVss provides immersive 
magnified (10×–15×) 3D high-definition view, fully restoring 
hand–eye coordination, tremor filtration, and scaled motion.17 
These tremendous technology improvements are particu-
larly rewarding, in comparison with standard laparoscopy, 
especially when delicate dissections or multiple incorporeal 
sutures are needed. Thus, the dVss would seem the ideal 
tool to make laparoscopic PD safely achievable by a larger 
population of pancreatic surgeons.
In this review, we have decided to consider only the 
articles reporting on ten or more patients to limit effect of the 
learning curve on reported outcomes.18 Actually, sufficient 
information is not available on the number of procedures 
that should be carried out to complete the learning curve 
for RAPD. It is instead likely that most surgeons practicing 
RAPD are still on their learning curve or have just completed 
it. This could be a bias when comparing the results of RAPD 
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with those of open PD. Further, it is likely that in their initial 
experience, most authors have preferred to avoid the most 
challenging operative scenarios. Typically, patients having 
easily resectable diseases have soft pancreatic remnants with 
small ducts. It is known that these circumstances increase the 
rate and severity of POPF,19 making meaningful comparison 
with open PD unfeasible.
Perhaps because RAPD is still in its infancy, all authors 
described different techniques. Even authors describing 
fully robotic RAPD used different techniques. This is not 
surprising, considering that the technique for open PD has 
not been standardized yet. Some of these differences, how-
ever, could be solved by the availability of the newer robotic 
generation, the dVss Xi. While the core technology and the 
basic working principles of the newer robotic system are 
unchanged, there are several innovations that could facili-
tate either the standardization of the surgical technique or a 
wider adoption of RAPD. The new system, indeed, permits 
camera hopping among ports, improves patient accessibil-
ity by the anesthesia team, increases internal work volume 
despite reducing the risk of inter-arm and patient collision 
while allowing for closer port positioning, and is expected 
to allow coordinated movements of the robotic arms with a 
specifically designed bed.
From a technical point of view, one of the surgical aspects 
that is not expected to change, even with the newer robotic 
system, is the method used to divide the pancreas neck, which 
is thought to be key in the development of POPF. In open 
surgery, a sharp division of the pancreatic neck is advised to 
preserve blood supply to the resection margin. Bleeding is 
partially prevented by placing stay sutures at the superior and 
inferior borders of the pancreatic neck, and arrested by indi-
vidually suturing spurting bleeders while noting the position 
of the main pancreatic duct.20 In RAPD, the division of the 
pancreatic neck employs different types of energy devices as 
sharp division is unpractical and a dry cut surface is preferable. 
All available energy devices are associated with lateral thermal 
spread, which induces collateral tissue injury.21–23
When considering feasibility, RAPD appears to be fea-
sible in most selected patients. Selection is indeed key, and 
there is no evidence that RAPD can be safely performed in 
an unselected population of patients. RAPD requires longer 
operative times when compared to open surgery. Reported 
incidence of conversion to open surgery ranged from 3.0% 
to 10.0%. Excluding patients who were not able to tolerate 
pneumoperitoneum, in most of the other patients, conver-
sion to open surgery was caused by tumor adherence to the 
superior mesenteric/portal vein, difficulties in achieving 
complete oncologic clearance, and challenging dissection. 
Most of these instances are potentially predictable. It is 
worth noting that timely conversion to open surgery should 
not be viewed as treatment failure, but should be rather con-
sidered prudent surgical practice. The entire team, including 
the operating room personnel, should be ready to face this 
occurrence, especially in case of bleeding. One intraopera-
tive death, caused by portal vein injury, was reported despite 
conversion to open surgery.5
While little doubt exists that robotic assistance increases 
operating costs,24 none of the available studies was specifi-
cally designed to provide full economic evaluation of RAPD. 
The study by Chalikonda et al5 actually provided only a 
generic estimation of operating costs without describing 
the methodology or reporting detailed results. The study by 
Boggi et al estimated the operating costs of RAPD, exceeding 
those of open PD, considering operative and anesthesia time, 
robotic equipment, laparoscopic disposable devices, and the 
cost of the robotic system as amortized by case, including 
maintenance.9 However, even this study did not provide full 
economic evaluation of RAPD, which includes four types 
of analyses: cost-minimization analysis, cost-effectiveness 
analysis, cost-benefit analysis, and cost-utility analysis.24
However, whether the additional costs of robotic assis-
tance are worth being covered cannot be answered only 
by economic analysis. Robotic assistance is expected to 
facilitate performance of some advanced operations that, 
like RAPD, are carried out in deep spaces and require both 
fine dissections and complex intracorporeal suturing. Should 
these advantages be confirmed, and proved to be associated 
with improved task quality and patient outcome, the initial 
investment in the robotic technology would be justified, thus 
significantly reducing the costs of robotic assistance.
Current results show that RAPD is safely feasible, with 
morbidity and mortality rates in the range reported for open 
PD. Perhaps when the learning curve is completed and when 
the results on patients with hard pancreatic remnants and 
dilated ducts are available, a clear advantage in comparison 
with open PD may become evident. At present, RAPD is 
safe enough to be implemented in specialized centers with 
sound laparoscopic background.
Based on this review, we believe that RAPD is here to 
stay, although nearly everything remains to be standard-
ized and demonstrated. As robotic technology continues to 
improve, current limitations of RAPD are expected to become 
the next challenges. Eventually, RAPD will be available to 
a larger proportion of patients at specialized centers. We 
discourage surgeons not dedicated to pancreatic surgery, not 
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having a sound background on advanced laparoscopic tech-
niques, and not having received a formal training in robotic 
surgery to pursue RAPD in the occasional patient.
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